spironolactone has been researched along with Postoperative Complications in 36 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective, randomized, open-label multicenter trial evaluated the efficacy of catheter-based renal denervation (Symplicity, Medtronic) versus intensified pharmacological treatment including spironolactone (if tolerated) in patients with true-resistant hypertension." | 9.20 | Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. ( Bednář, F; Branny, M; Čurila, K; Holaj, R; Jiravský, O; Kociánová, E; Nykl, I; Petrák, O; Rosa, J; Šomlóová, Z; Štrauch, B; Táborský, M; Toušek, P; Václavík, J; Waldauf, P; Widimský, J; Widimský, P; Zelinka, T, 2015) |
| "Aldosterone is a key component in this process." | 6.90 | Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial. ( Alexandre, J; Allouche, S; Beygui, F; Buklas, D; Chequel, M; Cholley, B; Dolladille, C; Fellahi, JL; Fischer, MO; Legallois, D; Milliez, P; Ollitrault, P; Parienti, JJ; Rozec, B; Saplacan, V, 2019) |
| " We conclude that aldosterone antagonists in the dosage used had no effect on the course of postoperative hyperaldosteronism." | 5.26 | Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists. ( Haschke, F; Parth, K; Wimmer, M, 1981) |
| "The combination of tolvaptan with conventional diuretics increases urine output without renal dysfunction and can be effective for postoperative fluid management and appropriate body weight reduction." | 5.22 | Effects of short-term administration of tolvaptan after open heart surgery. ( Iwahasi, T; Iwahori, A; Iwasaki, T; Koizumi, N; Maruno, K; Matsuyama, K; Nishibe, T; Ogino, H; Takahashi, S; Toguchi, K, 2016) |
| "This prospective, randomized, open-label multicenter trial evaluated the efficacy of catheter-based renal denervation (Symplicity, Medtronic) versus intensified pharmacological treatment including spironolactone (if tolerated) in patients with true-resistant hypertension." | 5.20 | Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. ( Bednář, F; Branny, M; Čurila, K; Holaj, R; Jiravský, O; Kociánová, E; Nykl, I; Petrák, O; Rosa, J; Šomlóová, Z; Štrauch, B; Táborský, M; Toušek, P; Václavík, J; Waldauf, P; Widimský, J; Widimský, P; Zelinka, T, 2015) |
| "Aldosterone is a key component in this process." | 2.90 | Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial. ( Alexandre, J; Allouche, S; Beygui, F; Buklas, D; Chequel, M; Cholley, B; Dolladille, C; Fellahi, JL; Fischer, MO; Legallois, D; Milliez, P; Ollitrault, P; Parienti, JJ; Rozec, B; Saplacan, V, 2019) |
| "Tolvaptan is an orally administered selective vasopressin 2 receptor antagonist that promotes aquaresis." | 2.82 | Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass. ( Hirai, H; Hosono, M; Kaku, D; Kubota, Y; Nakahira, A; Sasaki, Y; Shibata, T; Suehiro, S; Suehiro, Y, 2016) |
| "However, incidence of postoperative low cardiac output state (p < 0." | 1.48 | Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease . ( Bitran, D; Fink, D; Merin, O; Shavit, L; Silberman, S; Tauber, R, 2018) |
| "Treatment of primary aldosteronism (PA) aims at preventing or correcting hypertension, hypokalemia and target organ damage." | 1.43 | SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery. ( Amar, L; Chaffanjon, P; Kraimps, JL; Ménégaux, F; Steichen, O; Zinzindohoue, F, 2016) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| " We conclude that aldosterone antagonists in the dosage used had no effect on the course of postoperative hyperaldosteronism." | 1.26 | Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists. ( Haschke, F; Parth, K; Wimmer, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (58.33) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shavit, L | 1 |
| Silberman, S | 1 |
| Tauber, R | 1 |
| Merin, O | 1 |
| Bitran, D | 1 |
| Fink, D | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Suehiro, Y | 1 |
| Hosono, M | 1 |
| Shibata, T | 1 |
| Sasaki, Y | 1 |
| Hirai, H | 1 |
| Nakahira, A | 1 |
| Kubota, Y | 1 |
| Kaku, D | 1 |
| Suehiro, S | 1 |
| Alexandre, J | 1 |
| Ollitrault, P | 1 |
| Fischer, MO | 1 |
| Fellahi, JL | 1 |
| Rozec, B | 1 |
| Cholley, B | 1 |
| Dolladille, C | 1 |
| Chequel, M | 1 |
| Allouche, S | 1 |
| Legallois, D | 1 |
| Saplacan, V | 1 |
| Buklas, D | 1 |
| Beygui, F | 1 |
| Parienti, JJ | 1 |
| Milliez, P | 1 |
| Rosa, J | 1 |
| Widimský, P | 1 |
| Toušek, P | 1 |
| Petrák, O | 1 |
| Čurila, K | 1 |
| Waldauf, P | 1 |
| Bednář, F | 1 |
| Zelinka, T | 1 |
| Holaj, R | 1 |
| Štrauch, B | 1 |
| Šomlóová, Z | 1 |
| Táborský, M | 1 |
| Václavík, J | 1 |
| Kociánová, E | 1 |
| Branny, M | 1 |
| Nykl, I | 1 |
| Jiravský, O | 1 |
| Widimský, J | 1 |
| Steichen, O | 1 |
| Amar, L | 1 |
| Chaffanjon, P | 1 |
| Kraimps, JL | 1 |
| Ménégaux, F | 1 |
| Zinzindohoue, F | 1 |
| Matsuyama, K | 1 |
| Koizumi, N | 1 |
| Nishibe, T | 1 |
| Iwasaki, T | 1 |
| Iwahasi, T | 1 |
| Toguchi, K | 1 |
| Takahashi, S | 1 |
| Iwahori, A | 1 |
| Maruno, K | 1 |
| Ogino, H | 1 |
| Barba-Navarro, R | 1 |
| Tapia-Silva, M | 1 |
| Garza-Garcia, C | 1 |
| López-Giacoman, S | 1 |
| Melgoza-Toral, I | 1 |
| Vázquez-Rangel, A | 1 |
| Bazúa-Valenti, S | 1 |
| Bobadilla, N | 1 |
| Wasung de Lay, M | 1 |
| Baranda, F | 1 |
| Chawla, LS | 1 |
| Gamba, G | 1 |
| Madero, M | 1 |
| Khachab, M | 1 |
| Kanaan, A | 1 |
| Awad, D | 1 |
| Deeba, E | 1 |
| Osman, S | 1 |
| Nassar, CF | 1 |
| Chanoit, G | 1 |
| Bublot, I | 1 |
| Viguier, E | 1 |
| Ozaydin, M | 1 |
| Varol, E | 1 |
| Türker, Y | 1 |
| Peker, O | 1 |
| Erdoğan, D | 1 |
| Doğan, A | 1 |
| Ibrişim, E | 1 |
| Billings, FT | 1 |
| Pretorius, M | 1 |
| Schildcrout, JS | 1 |
| Mercaldo, ND | 1 |
| Byrne, JG | 1 |
| Ikizler, TA | 1 |
| Brown, NJ | 1 |
| Ringel, RE | 1 |
| Peddy, SB | 1 |
| ABBES, M | 1 |
| CAMBON, P | 1 |
| PAILLAUD, F | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Jariwalla, AG | 1 |
| Jones, CR | 1 |
| Lever, A | 1 |
| Hall, R | 1 |
| Haschke, F | 1 |
| Wimmer, M | 1 |
| Parth, K | 1 |
| Hofmockel, G | 1 |
| Heimbach, D | 1 |
| Bussen, D | 1 |
| Reincke, M | 1 |
| Frohmüller, HG | 1 |
| Brun, J | 1 |
| Magnin, F | 1 |
| Nahum, M | 1 |
| Ratto, GB | 1 |
| Motta, G | 1 |
| Meznik, F | 1 |
| Pflüger, G | 1 |
| Zhuber, K | 1 |
| Zekert, F | 1 |
| Black, JA | 1 |
| Challacombe, DN | 1 |
| Ockenden, BG | 1 |
| Thind, GS | 1 |
| Blakemore, WS | 1 |
| Zinsser, HF | 1 |
| Lvoff, R | 1 |
| Wilcken, DE | 1 |
| Merrem, B | 1 |
| Rost, W | 1 |
| Inberg, MV | 1 |
| Harjola, PT | 1 |
| Scheinin, TM | 1 |
| Sampson, D | 1 |
| Kirdani, RY | 1 |
| Sandberg, AA | 1 |
| Murphy, GP | 1 |
| Beyer, J | 2 |
| Sebening, F | 2 |
| Motin, J | 1 |
| Rochet, J | 1 |
| Oelert, H | 1 |
| Larcan, A | 1 |
| Calamai, M | 1 |
| Jacob, F | 1 |
| Eriksson, I | 1 |
| Birchall, R | 1 |
| Batson, HM | 1 |
| Frank, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Spironolactone and Perioperative Atrial Fibrillation Occurrence in Cardiac Surgery Patients: a Multicenter Randomized, Double-blind Study. The ALDOCURE Trial[NCT03551548] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2019-02-26 | Recruiting | ||
| RAAS, Inflammation, and Post-operative AF[NCT00141778] | Phase 2/Phase 3 | 455 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 0.7 |
| Spironolactone | 0.7 |
The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 1.4 |
| Ramipril | 2.0 |
| Spironolactone | 0 |
Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 11.6 |
| Ramipril | 13.8 |
| Spironolactone | 6.8 |
Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 10.6 |
| Spironolactone | 10.2 |
(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge
| Intervention | days (Mean) |
|---|---|
| Placebo | 6.8 |
| Ramipril | 5.7 |
| Spironolactone | 5.8 |
The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 27.2 |
| Ramipril | 27.8 |
| Spironolactone | 25.9 |
Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 2.7 |
| Ramipril | 1.3 |
| Spironolactone | 2.0 |
It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 1091.3 |
| Ramipril | 970.1 |
| Spironolactone | 576.4 |
C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ug/mL (Mean) | ||||
|---|---|---|---|---|---|
| Initiation of surgery | Postoperative day 1 | Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | |
| Placebo | 4.1 | 51.4 | 134.8 | 128.3 | 94.1 |
| Ramipril | 4.3 | 49.9 | 131.0 | 164.8 | 105.2 |
| Spironolactone | 3.9 | 64.3 | 127.8 | 189.4 | 126.5 |
Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 4.7 | 12.0 | 15.6 | 130.0 | 119.0 | 100.3 |
| Ramipril | 4.6 | 20.5 | 28.8 | 202.1 | 171.0 | 95.5 |
| Spironolactone | 6.6 | 11.3 | 17.4 | 145.7 | 164.9 | 109.6 |
Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 19.6 | 19.2 | 21.0 | 36.4 | 55.2 | 28.1 |
| Ramipril | 16.2 | 19.7 | 22.0 | 38.9 | 47.9 | 25.7 |
| Spironolactone | 17.3 | 17.3 | 20.1 | 34.0 | 48.9 | 31.0 |
1 review available for spironolactone and Postoperative Complications
| Article | Year |
|---|---|
[Aldosterone and aldosterone antagonists in surgery].
Topics: Adult; Aldosterone; Blood Volume; Brain Edema; Cardiac Surgical Procedures; Child; Digitalis Glycosi | 1971 |
7 trials available for spironolactone and Postoperative Complications
| Article | Year |
|---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Cardiopulmonary Bypass; Cardiovascular Surgical Pro | 2016 |
Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial.
Topics: Adult; Aldosterone; Aortic Valve; Atrial Fibrillation; Coronary Artery Bypass; Double-Blind Method; | 2019 |
Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study.
Topics: Adult; Aged; Antihypertensive Agents; Axotomy; Blood Pressure Monitoring, Ambulatory; Catheter Ablat | 2015 |
Effects of short-term administration of tolvaptan after open heart surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedu | 2016 |
The Effect of Spironolactone on Acute Kidney Injury After Cardiac Surgery: A Randomized, Placebo-Controlled Trial.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Double-Blind Method; Female; Humans; Intensive Car | 2017 |
[Changes in urinary sodium-potassium ratio after abdominal surgery].
Topics: Abdomen; Adolescent; Adult; Aged; Clinical Trials as Topic; Female; Gastrointestinal Motility; Human | 1971 |
28 other studies available for spironolactone and Postoperative Complications
| Article | Year |
|---|---|
Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease
.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Cardiac Output, Low; Cardiac Surgical Procedures; Fema | 2018 |
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Topics: Adrenalectomy; France; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Intraoperative Complic | 2016 |
Colectomy induces an aldosterone-mediated increase in jejunal glucose uptake in rats.
Topics: Animals; Body Weight; Colectomy; Colon; Diuretics; Glucose; Jejunum; Male; Postoperative Complicatio | 2017 |
Transient tricuspid valve regurgitation following surgical treatment of cor triatriatum dexter in a dog.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cor Triatriatum; Diuretics; Dog Dis | 2009 |
Association between renin-angiotensin-aldosterone system blockers and postoperative atrial fibrillation in patients with mild and moderate left ventricular dysfunction.
Topics: Adrenergic Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensi | 2010 |
Obesity and oxidative stress predict AKI after cardiac surgery.
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Body Mass Index; Ca | 2012 |
Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease.
Topics: Child; Fontan Procedure; Heart Defects, Congenital; Humans; Infant; Mineralocorticoid Receptor Antag | 2003 |
[APPLICATION OF ANTI-ALDOSTERONE DIURETICS TO THE TREATMENT OF LOCALIZED EDEMA OF THE EXTREMITIES IN CANCER PATIENTS].
Topics: Aldosterone; Breast Neoplasms; Diuretics; Edema; Extremities; Female; Humans; Mastectomy; Mineraloco | 1965 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Spironolactone and diabetic ketoacidosis.
Topics: Diabetic Ketoacidosis; Humans; Hyperkalemia; Male; Medication Errors; Middle Aged; Postoperative Com | 1981 |
Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists.
Topics: Adolescent; Aldosterone; Canrenoic Acid; Child; Child, Preschool; Heart Defects, Congenital; Hematoc | 1981 |
[Surgical interventions of the adrenal gland. Diagnosis and results of treatment].
Topics: Adolescent; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Adenoma; | 1994 |
[Transient and curable myasthenia appearing 3 years after lower right thymectomy].
Topics: Female; Humans; Middle Aged; Myasthenia Gravis; Neostigmine; Postoperative Complications; Pyridostig | 1977 |
[Use of a new water-soluble aldosterone-antagonist in surgery. Early clinical results].
Topics: Adult; Aged; Biliary Tract Diseases; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; | 1976 |
[Origin and treatment of the socalled "cast syndrome" following operations for scoliosis (author's transl)].
Topics: Adolescent; Adult; Body Constitution; Casts, Surgical; Child; Duodenum; Female; Gastrointestinal Dis | 1975 |
Nephrotic syndrome associated with bacteraemia after shunt operations for hydrocephalus.
Topics: Edema; Escherichia coli; Female; Fluorescent Antibody Technique; Glomerulonephritis; Humans; Hydroce | 1965 |
Direct current cardioversion in digitalized patients with mitral valve disease.
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardiac Complexes, Pr | 1969 |
Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Digital | 1972 |
[Soludactone and neurosurgical recovery].
Topics: Adrenal Cortex Hormones; Blood Gas Analysis; Brain Diseases; Brain Edema; Brain Injuries; Brain Neop | 1974 |
[Influencing postoperative water-electrolyte imbalance with spironolactone (verospirone)].
Topics: Brain Edema; Dose-Response Relationship, Drug; Humans; Neurosurgery; Postoperative Complications; Po | 1974 |
Role of the mesentericocaval shunt in the management of portal hypertension.
Topics: Adolescent; Adult; Diuretics; Duodenal Ulcer; Edema; Female; Follow-Up Studies; Gastrointestinal Hem | 1974 |
The aetiology of hypertension after renal transplantation in man.
Topics: Adrenalectomy; Aldosterone; Animals; Biological Assay; Carbon Radioisotopes; Cortisone; Humans; Hype | 1973 |
[Aldosterone-antagonists in heart surgery. Influence of the pre- and post-operative treatment using specific aldosterone-antagonists].
Topics: Administration, Oral; Diuresis; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Postoperative | 1973 |
[Postoperative use of Aldadiene potassium in patients with alloplastic heart valve prosthesis].
Topics: Acid-Base Equilibrium; Aortic Valve; Bicarbonates; Ethacrynic Acid; Furosemide; Heart Valve Prosthes | 1973 |
[Severe kaliopenia and electrolytic gradient disturbances in medico-surgical resuscitation. Value of a spironolactone with antialdosterone and catatoxic effect].
Topics: Brain Edema; Cardiac Surgical Procedures; Cardiovascular Diseases; Extracorporeal Circulation; Human | 1971 |
Severe hypernatremia complicating heart valve surgery. A preliminary report.
Topics: Aortic Valve; Aortic Valve Stenosis; Body Weight; Chlorides; Heart Failure; Heart Valve Prosthesis; | 1969 |
Test for pathologic secretion of aldosterone.
Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Diet; Humans; Hyperaldosteronism; Hyperplasia; Hypert | 1968 |
[On the management of postoperative motility of the intestines by aldosterone antagonists].
Topics: Aldosterone; Gastrointestinal Motility; Humans; Postoperative Complications; Potassium Deficiency; P | 1966 |